title: Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.
abstract: Glomerular injury is characterized by mesangial cell (MC) proliferation and matrix formation. We sought to determine if reducing the activity of cyclin-dependent kinase 2 (CDK2) with the purine analogue, Roscovitine, decreased MC proliferation in vitro and in vivo. Roscovitine (25 microM) inhibited FCS-induced proliferation (P < 0.0001) in cultured MC. Rats with experimental mesangial proliferative glomerulonephritis (Thy1 model) were divided into two groups. A prevention group received daily intraperitoneal injections of Roscovitine in DMSO (2.8 mg/kg) starting at day 1. A treatment group received daily Roscovitine starting at day 3, when MC proliferation was established. Control Thy1 rats received DMSO alone. MC proliferation (PCNA +/OX7 + double immunostaining) was reduced by > 50% at days 5 and 10 in the Roscovitine prevention group, and at day 5 in the treatment group (P < 0.0001). Early administration of Roscovitine reduced immunostaining for collagen type IV, laminin, and fibronectin at days 5 and 10 (r = 0.984; P < 0.001), which was associated with improved renal function (urinary protein/creatinine, blood urea nitrogen, P < 0.05). We conclude that reducing the activity of CDK2 with Roscovitine in experimental glomerulonephritis decreases cell proliferation and matrix production, resulting in improved renal function, and may be a useful therapeutic intervention in disease characterized by proliferation.
authors.affiliation: Department of Medicine, University of Washington, Seattle 98195, USA.
authors.forename: J W
authors.initials: JW
authors.lastname: Pippin
authors.forename: Q
authors.initials: Q
authors.lastname: Qu
authors.forename: L
authors.initials: L
authors.lastname: Meijer
authors.forename: S J
authors.initials: SJ
authors.lastname: Shankland
mesh_terms: D000818:Animals; D042846:CDC2-CDC28 Kinases; D002453:Cell Cycle / Q000187:drug effects* / Q000502:physiology; D002467:Cell Nucleus / Q000187:drug effects* / Q000648:ultrastructure; D002478:Cells, Cultured; D003094:Collagen / Q000096:biosynthesis; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005353:Fibronectins / Q000096:biosynthesis; D005920:Glomerular Mesangium / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D015432:Glomerulonephritis, Membranoproliferative / Q000473:pathology* / Q000503:physiopathology*; D007677:Kidney Function Tests; D007797:Laminin / Q000096:biosynthesis; D011494:Protein Kinases / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D011687:Purines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D000077546:Roscovitine
chemical_list: D004791:Enzyme Inhibitors; D005353:Fibronectins; D007797:Laminin; D011687:Purines; D000077546:Roscovitine; D003094:Collagen; D011494:Protein Kinases; C102333:histone H1 kinase; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495892:Cdk2 protein, rat; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases